|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005516,
umls-concept:C0006610,
umls-concept:C0009780,
umls-concept:C0032923,
umls-concept:C0033684,
umls-concept:C0036667,
umls-concept:C0085201,
umls-concept:C0312418,
umls-concept:C0677886,
umls-concept:C1306673,
umls-concept:C1423594,
umls-concept:C1538046,
umls-concept:C2346918,
umls-concept:C2349975
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2011-8-8
|
|
pubmed:abstractText |
The low prevalence of ovarian cancer demands both high sensitivity (>75%) and specificity (99.6%) to achieve a positive predictive value of 10% for successful early detection. Utilizing a two stage strategy where serum marker(s) prompt the performance of transvaginal sonography (TVS) in a limited number (2%) of women could reduce the requisite specificity for serum markers to 98%. We have attempted to improve sensitivity by combining CA125 with proteomic markers.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/21708402-10770278,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21708402-11006025,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21708402-1399109,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21708402-15313933,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21708402-16061277,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21708402-16225703,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21708402-16237736,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21708402-16985025,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21708402-18395030,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21708402-19282241,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21708402-19291297,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21708402-19879639,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21708402-19955909,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21708402-20368574,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21708402-2651469,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21708402-6310399,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21708402-8634992
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Apolipoprotein A-I,
http://linkedlifedata.com/resource/pubmed/chemical/CA-125 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/MUC16 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Prealbumin,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/connective tissue-activating peptide
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1095-6859
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011. Published by Elsevier Inc.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
122
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
548-53
|
|
pubmed:dateRevised |
2011-9-26
|
|
pubmed:meshHeading |
pubmed-meshheading:21708402-Apolipoprotein A-I,
pubmed-meshheading:21708402-CA-125 Antigen,
pubmed-meshheading:21708402-Case-Control Studies,
pubmed-meshheading:21708402-Female,
pubmed-meshheading:21708402-Humans,
pubmed-meshheading:21708402-Membrane Proteins,
pubmed-meshheading:21708402-Middle Aged,
pubmed-meshheading:21708402-Neoplasm Staging,
pubmed-meshheading:21708402-Neoplasms, Glandular and Epithelial,
pubmed-meshheading:21708402-Ovarian Neoplasms,
pubmed-meshheading:21708402-Peptide Fragments,
pubmed-meshheading:21708402-Peptides,
pubmed-meshheading:21708402-Prealbumin,
pubmed-meshheading:21708402-Proteomics,
pubmed-meshheading:21708402-Reproducibility of Results,
pubmed-meshheading:21708402-Sensitivity and Specificity,
pubmed-meshheading:21708402-Spectrometry, Mass, Matrix-Assisted Laser...,
pubmed-meshheading:21708402-Tumor Markers, Biological
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
|
|
pubmed:affiliation |
U.T. M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA. chclarke@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
